The EPO published European Patent EP4007601A2 for a PCV2 (Porcine Circovirus Type 2) vaccine developed by NDSU Research Foundation and Biological Mimetics, Inc. The patent (Inventors: RAMAMOORTHY, Sheela; NARA, Peter) covers vaccine compositions including live attenuated virus formulations classified under IPC codes A61K 39/12, C07K 14/005, and C12N 7/00. The patent is validated in 38 designated contracting states including DE, FR, GB, IT, ES, NL, and others.\n\nPatent holders and biotechnology companies should note that this granted patent establishes IP rights that may affect competitive vaccine development in the PCV2 space. Third parties wishing to develop similar vaccines may need licensing agreements. This is a routine patent publication with no compliance deadlines or regulatory obligations.